HK2 and non-small cell lung carcinoma: The activity of hexokinase-2 was investigated in other malignancies such as non-small cell lung cancer and breast cancer and it was suggested that hexokinase-2 has a negative impact on the treatment of cancer by promoting chemoresistance and the inhibition of glycolysis through hexokinase-2 increases the cancer cells chemotherapy sensitivity [64,65,66].